Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03112174
Title Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Pharmacyclics LLC.
Indications

mantle cell lymphoma

Therapies

Ibrutinib

Ibrutinib + Venetoclax

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.